Weight usually comes back when GLP-1 therapy stops. Your plan shouldn't stop with it.
Email-gated download via Gumroad. We don't send marketing.
Written to the same standard as the paid catalog. Read the methodology
Five-page clinical resource for patients stopping or pausing semaglutide, tirzepatide or another GLP-1 medicine, for cost, supply, side effects, pregnancy planning or surgery. Drawn from the Stopping, Pausing & Maintenance section (Chapter 7) of the GLP-1 Nutrition Handbook, Second Edition (November 2026).
The evidence on one page: STEP-1 extension, STEP-4, SURMOUNT-4 and the 2026 BMJ meta-analysis of 37 studies, with what each finding means in clinic. A four-phase transition plan with protein targets from the 2025 Joint Advisory and the 2026 EASO/EFAD/ECPO consensus, and monitoring from the consensus. A short patient script for the "will I put it all back on?" conversation. Practice guidance is labelled as practice guidance.
Weight-management, endocrinology and primary care dietitians whose patients are stopping or pausing GLP-1 therapy.
5-page PDF · A4 print-ready · Free download · Evidence: 2025 Joint Advisory · 2026 EASO/EFAD/ECPO Consensus · SURMOUNT-4 · BMJ 2026 · Single-clinician licence · Dietitian-only resource
